top of page
Portfolio: Portfolio
Office Building


New Rhein Funds 2 and 3 have invested in six companies developing proprietary drug/device platforms for the treatment of COPD, BPH, COVID-19, migraine etc.


Past Deals

Prior investments have included medicines for Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics.  

novagali logo.jfif

Novagali was a French ophthalmology

 company developing products for Dry Eye Disease and Glaucoma.  The company was acquired by Santen for $139M in 2011.

bottom of page